90503-06-3

Basic information

• Product Name: AzithroMycin N-Oxide
• Synonyms: Azithromycin N-Oxide (15 mg);(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-;Azithromycin EP Impurity L;Azithromycin 3-N-Oxide;Azithromycin Impurity V;Azithromycin Impurity L(BP)
• CAS NO: 90503-06-3
• Molecular Formula: C38H72N2O13
• Molecular Weight: 764.98388
• Product Categories: Chiral Reagents;Impurities;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 90503-06-3.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• PKA: 12.51±0.60(Predicted)
• CAS DataBase Reference: AzithroMycin N-Oxide(CAS DataBase Reference)
• NIST Chemistry Reference: AzithroMycin N-Oxide(90503-06-3)
• EPA Substance Registry System: AzithroMycin N-Oxide(90503-06-3)

Safety Data

• Hazardous Substances Data: 90503-06-3(Hazardous Substances Data)

Upstream product

• 83905-01-5 Zithromax(R) 

Downstream Products

• 172617-84-4 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)‐2‐ethyl‐3,4,10‐trihydroxy‐13‐{(2R,4R,5S,6S)‐5‐hydroxy‐4‐methoxy‐4,6‐dimethyl-tetrahydropyran‐2‐yloxy}‐11‐{(2S,3R,4S,6R)‐3‐hydroxy‐6‐methyl‐4‐methylamino-tetrahydropyran‐2‐yloxy}‐3,5,6,8,10,12,14‐heptamethyl‐1‐oxa‐6‐azacyclopentadecan‐15‐one 

Relevant articles and documents

Macrocyclic lactone impurity synthetic method

The invention relates to a method for preparing an azithromycin impurity I and an azithromycin impurity E. The method comprises the following steps: mixing azithromycin with a solvent, and adding the mixture into a compound which is shown as (I) in the description to perform a demethylation reaction, wherein R1 and R2 are respectively and independently methyl, ethyl, propyl, naphthenic group, a phenyl and p-methylphenyl. According to the method for preparing azithromycin impurity, the reaction is carried out under a mild condition; the method can be used for preparing the azithromycin impurity I and the azithromycin impurity E by controlling the amount of a reagent; the HPLC purity of the azithromycin impurities prepared by the method is 98 percent or more.

9A-AZALIDES WITH ANTI-INFLAMMATORY ACTIVITY

Macrolides with anti-inflammatory activity are described, and more particularly, 9a-azalides without cladinose in position 3 with anti-inflammatory activity, their pharmaceutically acceptable salts and pharmaceutical compositions that contain them as active principle.